Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

ECLIPSE: Balloon Angioplasty as Good as Orbital Atherectomy in Calcified Lesions

News Conference News TCT 2024

ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty in Calcified Lesions

Yael L. Maxwell

October 29, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

September 22, 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

News Conference News TCT 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

October 22, 2021

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

October 14, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.